SEC 8-K
SEC 8-K: Item 1.01, 2.03, 8.01, 9.01
Official SEC filing update. Items: 1.01, 2.03, 8.01, 9.01.
Item 1.01, 2.03, 8.01, 9.01Accession 0001104659-26-064518
Gilead Sciences (GILD) Financials, Dividends & Stock Info
Explore comprehensive financial data for Gilead Sciences, provided completely free. Analyze revenue, net income, profit margins, dividend history, and key financial ratios to make informed investment decisions.
Data as of (573 days ago)|Source: SEC EDGAR
The information on this page is for informational purposes only and does not constitute investment advice, financial advice, or any recommendation. Billiver does not recommend buying, selling, or holding any security. Past performance is not indicative of future results.
Data may be delayed and accuracy is not guaranteed. All investment decisions are solely your responsibility. Verify information independently and consult a qualified financial advisor before investing. About · Methodology
GILDHealth Care
Gilead Sciences (GILD) is a biotechnology company. The company reports annual revenue of $29.1B and net income of $8.1B. Its profit margin is 27.9%.
Gilead Sciences Key Financials(TTM Est.)
Revenue (TTM)↑ 2.4%
$29.1B
Net Income (TTM)↑ 1672.9%
$8.1B
Profit Margin
27.9%
Top 35% in sector
Return on Equity
37.6%
Top 20% in sector
Debt/Equity
1.16
Top 33% in sector
Data from SEC EDGAR filings. TTM = Trailing Twelve Months.
Gilead Sciences Financial Health ScoreFY2025
0/100
Good overall health with some areas for improvement
+14 pts YoYProfitability93Liquidity100Solvency55Growth50Cash Flow100Efficiency65
This Financial Health Score is a proprietary metric calculated from SEC EDGAR filings for educational and informational purposes only. It does not constitute investment advice or a recommendation to buy or sell any security. Results vary significantly by industry. Conduct your own research before making investment decisions.
Data Highlights
- Strong profit margin: 27.9%
- Strong return on equity: 37.6%
Data sourced from SEC EDGAR filings. Not investment advice.
Gilead Sciences Official SEC Updates
Official filing updates from SEC EDGAR. Billiver stores internal evidence snapshots for verification, but this page links to the SEC source instead of republishing full filing text.
Open SEC filing
SEC 10-Q
SEC 10-Q
Official SEC filing update.
10-QAccession 0000882095-26-000024
SEC 8-K
SEC 8-K: Item 2.02, 9.01
Official SEC filing update. Items: 2.02, 9.01.
Item 2.02, 9.01Accession 0000882095-26-000022
SEC 8-K
SEC 8-K: Item 5.07, 9.01
Official SEC filing update. Items: 5.07, 9.01.
Item 5.07, 9.01Accession 0000882095-26-000008
SEC 8-K
SEC 8-K: Item 7.01, 8.01, 9.01
Official SEC filing update. Items: 7.01, 8.01, 9.01.
Item 7.01, 8.01, 9.01Accession 0001104659-26-049874
Source: SEC EDGAR · 5 filings
Informational only. Not investment advice.
Gilead Sciences Recent Events
Material Agreement
Other Events
Earnings Results
Shareholder Vote
Other Events
Source: SEC EDGAR 8-K Filings
5-Year Revenue & Net Income Trend
Chart shows fiscal year data from SEC EDGAR filings. Hover over data points for details.
As of FY2025 · SEC 10-K · Updated Jun 30, 2026
Revenue Breakdown (FY2024)
See Gilead Sciences detailed breakdown →Product
$28.6B99.5%
HIVProductsDescovy
$2.1B7.3%
HIVProductsSymtuzaRevenueShare
$592M2.1%
Showing top 3 of 4 segments
About Gilead Sciences
Gilead Sciences, Inc. is an American biopharmaceutical company headquartered in Foster City, California, that focuses on researching and developing antiviral drugs used in the treatment of HIV/AIDS, hepatitis B, hepatitis C, influenza, and COVID-19, including ledipasvir/sofosbuvir and sofosbuvir. Gilead is a member of the Nasdaq-100 and the S&P 100.
- Industry
- Biotechnology
Valuation
Valuation Data UnavailablePrice-based valuation metrics (P/E, P/B) require real-time stock price data which is not included in SEC filings.
Benjamin Graham: Graham recommended P/E ratio not exceed 15 for reasonable valuation. Understanding valuation metrics
Profitability
Above-Average MarginsROE37.6%
vs 14.8% sector median / 21.8% avg
▼
Generates $37.6 in profit for every $100 of shareholder equity. Higher than 80% in Health Care.
Profit Margin27.9%
vs 18.1% sector median / 15.0% avg
▼
Keeps 28 cents of every dollar in revenue as profit. Higher than 65% in Health Care.
Revenue (TTM)*$29.1B
4th consecutive year of revenue growth.
Net Income (TTM)*$8.1B
* Some quarterly data is missing. Values are calculated based on annual report figures.
Profit margin 86% above sector average.
Warren Buffett: Buffett looks for consistent ROE above 20% as a sign of competitive advantage. How to evaluate profitability
Financial Health
Above-Average LeverageDebt/Equity1.16
vs 1.48 sector median / 2.01 avg
▼
Carries $1.16 in debt for every $1 of equity. Lower debt than 67% in Health Care.
Total Debt$24.9B
Debt-to-equity ratio of 1.16 is above 1. Debt is 42% below sector average.
Peter Lynch: Lynch: normal balance sheet has 75% equity, 25% debt. Understanding financial health
Dividend
Dividend Data UnavailableDividend yield data is not available from SEC filings. Check the company's investor relations page for dividend information.
As of FY2025 · SEC 10-K · Updated Jun 30, 2026
Gilead Sciences 10-Year Revenue, Profit & Cash Flow History
Annual Financials
FY2025 - FY2016| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $29.4B(+2.4%) | $28.8B(+5.3%) | $27.3B(+10.6%) | $24.7B(+10.0%) | $22.4B(-9.1%) | $24.7B(-5.4%) | $26.1B(-14.1%) | $30.4B(-6.9%) | $32.6B(+31.1%) | $24.9B(-23.7%) |
| Net Income | $8.5B(+1672.9%) | $480.0M(-92.3%) | $6.2B(+4961.0%) | $123.0M(-97.7%) | $5.4B(+4278.9%) | $123.0M(-97.3%) | $4.6B(-65.7%) | $13.5B(-25.4%) | $18.1B(+49.6%) | $12.1B(-33.2%) |
| Total Assets | $59.0B | $59.0B | $62.1B | $63.2B | $68.0B | $68.4B | $61.6B | $63.7B | $70.3B | $57.0B |
| Total Debt | $24.9B | $26.7B | $25.0B | $25.2B | $26.7B | $31.4B | $22.1B | $24.6B | $30.8B | $26.3B |
| Total Equity | $22.7B | $19.3B | $22.8B | $21.2B | $21.1B | $18.2B | $22.5B | $21.4B | $20.4B | $18.9B |
| Profit Margin | 28.9% | 1.7% | 22.8% | 0.5% | 24.0% | 0.5% | 17.7% | 44.4% | 55.5% | 48.6% |
| ROE | 37.5% | 2.5% | 27.3% | 0.6% | 25.6% | 0.7% | 20.5% | 63.1% | 88.6% | 64.1% |
| ROA | 14.4% | 0.8% | 10.0% | 0.2% | 7.9% | 0.2% | 7.5% | 21.2% | 25.8% | 21.2% |
Quarterly Financials
Last 8 quarters| Metric | Q1 2026 | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 | Q1 2024 | Q3 2023 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $6.7B | $21.2B | $13.6B | $6.7B | $20.0B | $13.0B | $6.4B | $19.9B |
| Net Income | $1.3B | $-1,303,000,000 | $-2,556,000,000 | $-4,170,000,000 | $4.2B | $2.1B | $1.0B | $3.0B |
| Total Assets | $59.0B | $59.0B | $59.0B | $59.0B | $62.1B | $62.1B | $62.1B | $63.2B |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026
Insider Trading
Loading chart...
Loading transactions...
Source: SEC EDGAR Form 4 filings. Only purchase (P) and sale (S) transactions shown.
Gilead Sciences Dividend Safety Analysis & Growth History
Dividend Status
Dividend PayerCAGR (5Y)
-2.7%
CAGR (10Y)
+6.3%
This company pays dividends. Historical dividend data shown below.
5-year dividend CAGR: -2.7%.
Annual Dividends
2016 - 2025| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Dividend/Share | $1.84 | $2.08 | $2.28 | $2.52 | $2.72 | $2.84 | $2.92 | $3.00 | $3.08 | $2.37 |
| YoY Growth | +42.6% | +13.0% | +9.6% | +10.5% | +7.9% | +4.4% | +2.8% | +2.7% | +2.7% | -23.1% |
| Payments | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 3 |
| Increased | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | No |
Learn more: Dividend investing guide | How to evaluate dividend safety
As of FY2025 · SEC 10-K · Updated Jun 30, 2026
Gilead Sciences Free Cash Flow & Dividend Coverage
Free Cash Flow
$9.5B
FY2025
FCF Margin
32.1%
FCF / Revenue
Operating Cash Flow
$10.0B
Cash from operations
FCF / Net Income
1.11x
Quality earnings
Generates approximately $26M in free cash flow per day.
Cash Flow History
FY2016 - FY2025| Metric | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating CF | $12.8B | $21.3B | $17.0B | $11.9B | $8.2B | $9.1B | $8.2B | $11.4B | $10.8B | $10.0B |
| CapEx | -$557.0M | -$747.0M | -$748.0M | -$590.0M | -$650.0M | -$825.0M | -$650.0M | -$579.0M | -$523.0M | -$563.0M |
| Free Cash Flow | $12.3B | $20.5B | $16.3B | $11.3B | $7.5B | $8.3B | $7.5B | $10.8B | $10.3B | $9.5B |
| FCF Margin | 49.3% | 62.8% | 53.6% | 43.3% | 30.4% | 37.1% | 30.4% | 39.6% | 35.8% | 32.1% |
Source: SEC EDGAR 10-K filings. FCF = Operating Cash Flow - Capital Expenditures. Free cash flow guide
As of FY2025 · SEC 10-K · Updated Jun 30, 2026
Gilead Sciences Risk Factors
Company-disclosed SEC risk factors
Risk factors are disclosed by the company in its SEC Form 10-K, Item 1A. Billiver does not classify or summarize company-specific legal, operational, financial, or market risks here.
Sector context: Health Care. This is not a Billiver risk assessment for GILD.
Source note: the SEC Form 10-K includes Item 1A, "Risk Factors." The full risk-factor text should be read from the company’s own SEC filing.
Gilead Sciences FAQ
What is Gilead Sciences's annual revenue?
Gilead Sciences (GILD) reported $29.1 billion in trailing twelve-month (TTM) revenue. This financial data is compiled from SEC EDGAR 10-K filings.
Is Gilead Sciences profitable?
Yes, Gilead Sciences is profitable with a 27.9% net profit margin and $8.1 billion in net income (TTM). All figures from SEC EDGAR 10-K filings.
Does Gilead Sciences pay dividends?
Yes, Gilead Sciences pays regular dividends. View the full dividend history and payout analysis on this page.
What is Gilead Sciences's financial health score?
Gilead Sciences has a financial health score of 77/100 (Grade: B), evaluating profitability, solvency, liquidity, and growth based on SEC EDGAR data.
How many years of Gilead Sciences financial data are available?
10 years of financial data are available for Gilead Sciences from FY2016 to FY2025. All figures are compiled from SEC EDGAR 10-K filings.